Issue of Equity

RNS Number : 0337H
Avacta Group PLC
14 May 2014
 



 

 

 

 

 

Avacta Group plc

("Avacta" or the "Group")

 

Issue of Equity

 

Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for human and animal healthcare, today announces that 3,779,411 Ordinary Shares of 0.1p ("new Ordinary Shares") have been issued by the Company pursuant to the exercise of share options by former employees.

 

Application will be made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 19 May 2014.

 

The total number of Ordinary Shares in issue following the above issue will be 4,029,831,367 each with voting rights.  No Ordinary Shares are held in Treasury.

 

The above figure of 4,029,831,367 shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FSA's Disclosure and Transparency Rules.

 

 

- Ends -

 

Enquiries:

Avacta Group plc

Tel:  +44 (0) 844 414 0452

Alastair Smith, Chief Executive Officer

www.avacta.com

Tim Sykes, Chief Financial Officer




Numis Securities Limited

Tel:  +44 (0) 207 260 1000

Michael Meade / Freddie Barnfield - Nominated Adviser

www.numiscorp.com

James Black - Corporate Broking




Walbrook PR Ltd

   Tel: +44 (0) 20 7933 8780 or avacta@walbrookpr.com

Paul McManus

Mob: +44 (0)7890 541 893

Lianne Cawthorne

Mob: +44 (0)7584 391 303

 

 

 

 

 

 

 

 

 

 

 

 

About Avacta Group plc - www.avacta.com

 

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through three divisions:

 

Avacta Analytical

www.avactaanalytical.com

 

High throughput analysis instrument, Optim, to help reduce the cost and risk of drug development.

Avacta Animal Health

www.avactaanimalhealth.com

 

Veterinary diagnostics reference laboratory, diagnostic kits and newly launched in-clinic blood analyser, Sensipod.

Avacta Life Sciences

www.avactalifesciences.com

 

Novel non-antibody affinity reagents called Affimers, with a wide range of Life Science applications in diagnostics, drug and biomarker discover and biotech research and development.

 

Avacta joined AIM in August 2006 and is based in Wetherby, England.

 

 

 

 

 

 

 

 

 

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEUOUKRSRAVAAR
UK 100